[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356475-105":59,"doc-detail-356475-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-management-of-menopause-in-women-with-philadelphia-negative-myeloproliferative-neoplasms-clinical-challenges-and-therapeutic-considerations","The Management of Menopause in Women with Philadelphia-Negative Myeloproliferative Neoplasms - Clinical Challenges and Therapeutic Considerations","","Philadelphia-Negative myeloproliferative neoplasms (MPNs) are chronic clonal hematopoietic malignancies defined by dysregulated myeloid proliferation, chronic inflammation, and elevated risk of thrombotic and hemorrhagic complications. Beyond disease morbidity, women may experience a substantial symptom burden that overlaps with menopausal complaints. Menopause-related hormonal changes further complicate assessment and management because disease-specific guidance for menopause care and the thrombotic risk concerns around hormone replacement therapy remain limited. This narrative review synthesizes evidence on menopause in this population, emphasizing HRT safety, non-hormonal options, supportive strategies, and a pragmatic clinical algorithm.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-management-of-menopause-in-women-with-philadelphia-negative-myeloproliferative-neoplasms-clinical-challenges-and-therapeutic-considerations/356475/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-management-of-menopause-in-women-with-philadelphia-negative-myeloproliferative-neoplasms-clinical-challenges-and-therapeutic-considerations/356475.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is menopause management particularly challenging in women with Philadelphia-negative MPNs?","Question",{"text":112,"@type":113},"Menopausal symptoms can overlap with MPN-related symptoms, making clinical assessment difficult. Guidance is also limited because hormone replacement therapy raises concerns about thrombotic risk.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What major complications in Philadelphia-negative MPNs influence care decisions?",{"text":117,"@type":113},"The article highlights dysregulated myeloid proliferation with chronic inflammation and increased thrombotic and hemorrhagic complications, which can affect risk-benefit decisions.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the review focus on regarding treatment strategies?",{"text":121,"@type":113},"It summarizes evidence on the safety and role of hormone replacement therapy, discusses non-hormonal therapeutic alternatives, and outlines supportive care strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356475,1790545158,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Review  \nThe Management of Menopause in Women with Philadelphia-Negative Myeloproliferative Neoplasms: Clinical Challenges and Therapeutic Considerations  \nClaire Woodley  and Priya Sriskandarajah *  \nAcademic Editor: Steven Knapper  \nReceived: 29 January 2026  \nRevised: 16 February 2026  \nAccepted: 19 February 2026  \nPublished: 24 February 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nDepartment of Haematology, Guy’s Hospital, London SE1 9RT, UK; [clairewoodley@nhs.net](clairewoodley@nhs.net)  \n* [Correspondence: priya.sriskandarajah@nhs.net](Correspondence: priya.sriskandarajah@nhs.net)  \nSimple Summary  \nPhiladelphia-Negative Myeloproliferative neoplasms (MPNs) are chronic blood cancers that can be associated with significant symptoms. These can impact patients’ quality of life and thus require close management. In women, particularly those going through menopause, the symptom burden can increase. However, due to the crossover of symptoms between menopause and MPN, it can be difficult to delineate the two conditions in these patients. This is compounded by the lack of guidance around the use of hormone replacement therapy in MPN patients due to the potential risk of thrombosis. Our review aims to assess evidence to date around menopause and MPN and highlight potential therapy strategies to consider in these patients.  \nAbstract  \nPhiladelphia-Negative Myeloproliferative neoplasms (MPNs) are chronic clonal hematopoietic malignancies characterized by dysregulated myeloid proliferation, chronic inflammation, and an increased risk of thrombotic and hemorrhagic complications. In addition to disease-related morbidity, MPNs are associated with a substantial symptom burden that significantly impacts quality of life. Menopause is accompanied by hormonal changes that can produce symptoms overlapping with those of MPNs, complicating clinical assessment and management in affected women. This challenge is further compounded by the lack of disease-specific guidance on menopause management in women with MPNs and ongoing concerns regarding the thrombotic risk associated with hormone replacement therapy (HRT) . This narrative review summarizes the current evidence on menopause in women with Philadelphia chromosome–negative MPNs, with particular focus on the safety and role of HRT, non-hormonal therapeutic alternatives, and supportive care strategies. We also propose a pragmatic clinical algorithm to support individualized menopause management in this high-risk population.  \nKeywords: menopause; myeloproliferative neoplasms; hormone replacement therapy  \n1. Introduction  \nMyeloproliferative neoplasms (MPNs) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by excessive production of mature myeloid blood cells. The classical Philadelphia chromosome-negative MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), with disease pathogenesis most commonly driven by acquired mutations in JAK2, CALR, and MPL genes [1] . These  \ndisorders are associated with chronic inflammation, splenomegaly, progressive marrow dysfunction and elevated risks of arterial and venous thrombosis [1,2] .  \nSex and gender have emerged as central determinants of disease biology, clinical phenotype, and outcomes in cancers [3] . Furthermore, recent data have identified sexdependent differences at the level of hematopoietic stem cells, impacting hemopoiesis, leukemogenesis and certain gene functions [4] . In the context of MPNs, it is well documented that women demonstrate distinct phenotypic profiles compared to men, with higher frequencies of essential thrombocytosis and unique thrombotic and vascular patterns that influence diagnosis and management [5–7] . Importantly, sex has been associated with differential symptom burden in ","cbCaihmOuzYXNQ7h","https://ap.wps.com/l/cbCaihmOuzYXNQ7h","pdf",1074633,16,"English","# Introduction\n## Definition and scope of menopause management\n## MPN biology and sex-related clinical differences\n## Clinical challenges in women with Philadelphia-negative MPNs","[{\"question\":\"Why is menopause management particularly challenging in women with Philadelphia-negative MPNs?\",\"answer\":\"Menopausal symptoms can overlap with MPN-related symptoms, making clinical assessment difficult. Guidance is also limited because hormone replacement therapy raises concerns about thrombotic risk.\"},{\"question\":\"What major complications in Philadelphia-negative MPNs influence care decisions?\",\"answer\":\"The article highlights dysregulated myeloid proliferation with chronic inflammation and increased thrombotic and hemorrhagic complications, which can affect risk-benefit decisions.\"},{\"question\":\"What does the review focus on regarding treatment strategies?\",\"answer\":\"It summarizes evidence on the safety and role of hormone replacement therapy, discusses non-hormonal therapeutic alternatives, and outlines supportive care strategies.\"}]","The Management of Menopause in Women with Philadelphia-Negative Myeloproliferative Neoplasms - Clinical Challenges and Therapeutic Considerations | PDF",1790125502,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59316d3d3275e006ee2b0564d0e08cec.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0867bff177445fe1073bc1fa1c86f648.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f27e5873c0a3ebf19a81cd555c85ed16.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c405d0fa3f9b056be747043cbdf64bc7.webp",980,1385]